Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Apr 01, 2007 (Vol. 27, No. 7)

The Company of Biologists Limited

URL:www.biologists.com/web/index.html
  • Intriguing idea
  • Nothing significant
I like the tagline on this one—A charity run by biologists for biologists. The title is a bit misleading, inasmuch as the site provides online scientific research journals via the Open Access Initiative. As the site notes, authors can publish their work free of charge in a traditional publication format or by paying for a subscription-free format that provides visitors completely free access to the material. The site, from the descriptions, appears to be a bit of an experiment, and it sounds like a worthwhile one. Three journals are offered by the publisher: Development, Journal of Cell Science, and The Journal of Experimental Biology. The company also provides travel grants and fellowships of up to $4,000 to postdocs interested in collaborations with other laboratories.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »